Against the COVID-19 backdrop, many U.S. public companies should consider the advisability of the adoption of a shareholder rights plan (also referred to as a “poison pill”) to protect against opportunistic share purchases by would-be activists or hostile acquirers, or to protect potentially valuable NOLs from a value-destructive “change of control” under the current U.S. tax code.
Please download our white paper to learn more.
*The file is an Adobe Acrobat PDF. If you experience difficulty opening the downloadable file, you may need to download the free Acrobat Reader.
Mark Mikullitz Managing Director, Head of Shareholder Activism ServicesRick Lacher Managing Director, Co-Head of Board and Special Committee AdvisoryGary Finger Special AdvisorRobert G. Rosenberg Managing Director, Co-Head of Transaction Opinions and Board AdvisoryAndrew Stull Managing Director, Transaction OpinionsRichard De Rose Managing Director, Transaction OpinionsChristopher Glad Director, Corporate Valuation Advisory ServicesWinston Shows Senior Vice President, M&A Tax
The link below leads to a website that is not owned by Houlihan Lokey. Continue to the external website, or close the window to remain on HL.com